Literature DB >> 24832832

Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria.

László Gulácsi1, Alexandru M Rotar, Maciej Niewada, Olga Löblová, Fanni Rencz, Guenka Petrova, Imre Boncz, Niek S Klazinga.   

Abstract

This paper describes and discusses the development and use of health technology assessment (HTA) in five Central and Eastern European countries (CEE): Poland, the Czech Republic, Hungary, Romania and Bulgaria. It provides a general snapshot of HTA policies in the selected CEE countries to date by focusing on country case-studies based on document analysis and expert opinion. It offers an overview of similarities and differences between the individual CEE countries and discusses in detail the role of HTA by assessing its formalization and institutionalization, standardization of methodology, the use of HTA in practice and the degree of professionalization of HTA in the region. It finds that HTA has been to some extent implemented in all five countries studied, with methodologies in accordance with international standards, but that challenges remain when it comes to the role of HTA in health care decision-making as well as to human resource capacities of the countries. This paper suggests that coming years will show whether CEE countries develop adequate national analytical capacity to assess and appraise technologies in the context of local need and affordability, instead of using HTA as a mere administrative procedure to fulfill (inter)national requirements. Finally, suggestions are provided to strengthen HTA in CEE countries through cooperation, mutual learning, a common accreditation of HTA bodies and increased network building among CEE HTA experts.

Entities:  

Mesh:

Year:  2014        PMID: 24832832     DOI: 10.1007/s10198-014-0590-8

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  9 in total

1.  Issues for countries considering introducing the "fourth hurdle": the case of Hungary.

Authors:  László Gulácsi; Imre Boncz; Michael Drummond
Journal:  Int J Technol Assess Health Care       Date:  2004       Impact factor: 2.188

2.  Health technology assessment in Poland and Scotland: comparison of process and decisions.

Authors:  Katarzyna Kolasa; Radek Wasiak
Journal:  Int J Technol Assess Health Care       Date:  2012-01       Impact factor: 2.188

3.  Applying rapid 'de-facto' HTA in resource-limited settings: experience from Romania.

Authors:  Ruth Lopert; Francis Ruiz; Kalipso Chalkidou
Journal:  Health Policy       Date:  2013-08-14       Impact factor: 2.980

4.  Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems.

Authors:  Nicola Allen; Franz Pichler; Tina Wang; Sundip Patel; Sam Salek
Journal:  Health Policy       Date:  2013-09-25       Impact factor: 2.980

Review 5.  The NICE cost-effectiveness threshold: what it is and what that means.

Authors:  Christopher McCabe; Karl Claxton; Anthony J Culyer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

6.  A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland.

Authors:  Katarzyna Kolasa; Sebastian Schubert; Andrea Manca; Tadeusz Hermanowski
Journal:  Health Policy       Date:  2011-10       Impact factor: 2.980

Review 7.  Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions.

Authors:  Irina Cleemput; Mattias Neyt; Nancy Thiry; Chris De Laet; Mark Leys
Journal:  Int J Technol Assess Health Care       Date:  2011-01-25       Impact factor: 2.188

8.  Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary.

Authors:  Dóra Endrei; Bálint Molics; István Agoston
Journal:  Value Health       Date:  2014-04-29       Impact factor: 5.725

9.  Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.

Authors:  Nicholas S Downing; Jenerius A Aminawung; Nilay D Shah; Harlan M Krumholz; Joseph S Ross
Journal:  JAMA       Date:  2014 Jan 22-29       Impact factor: 56.272

  9 in total
  18 in total

1.  Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries.

Authors:  Petra Baji; Manuel García-Goñi; László Gulácsi; Emmanouil Mentzakis; Francesco Paolucci
Journal:  Eur J Health Econ       Date:  2015-08-22

Review 2.  Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.

Authors:  Fanni Rencz; Márta Péntek; Martin Bortlik; Edyta Zagorowicz; Tibor Hlavaty; Andrzej Śliwczyński; Mihai M Diculescu; Limas Kupcinskas; Krisztina B Gecse; László Gulácsi; Peter L Lakatos
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 3.  Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries.

Authors:  László Gulácsi; Fanni Rencz; Márta Péntek; Valentin Brodszky; Ruth Lopert; Noémi V Hevér; Petra Baji
Journal:  Eur J Health Econ       Date:  2014-05-16

Review 4.  EQ-5D in Central and Eastern Europe: 2000-2015.

Authors:  Fanni Rencz; László Gulácsi; Michael Drummond; Dominik Golicki; Valentina Prevolnik Rupel; Judit Simon; Elly A Stolk; Valentin Brodszky; Petra Baji; Jakub Závada; Guenka Petrova; Alexandru Rotar; Márta Péntek
Journal:  Qual Life Res       Date:  2016-07-29       Impact factor: 4.147

Review 5.  The Value of Medicines: A Crucial but Vague Concept.

Authors:  Fernando Antoñanzas; Robert Terkola; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2016-12       Impact factor: 4.981

Review 6.  EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis.

Authors:  Zsombor Zrubka; Fanni Rencz; Jakub Závada; Dominik Golicki; Valentina Prevolnik Rupel; Judit Simon; Valentin Brodszky; Petra Baji; Guenka Petrova; Alexandru Rotar; László Gulácsi; Márta Péntek
Journal:  Rheumatol Int       Date:  2017-08-28       Impact factor: 2.631

7.  Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review.

Authors:  Peter Ghijben; Yuanyuan Gu; Emily Lancsar; Silva Zavarsek
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981

8.  Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria.

Authors:  Georgi Iskrov; Rumen Stefanov
Journal:  Balkan Med J       Date:  2016-01-01       Impact factor: 2.021

9.  Cost of illness of medically treated benign prostatic hyperplasia in Hungary.

Authors:  Fanni Rencz; Ágnes Kovács; Valentin Brodszky; László Gulácsi; Zalán Németh; Gábor János Nagy; János Nagy; István Buzogány; Géza Böszörményi-Nagy; Attila Majoros; Péter Nyirády
Journal:  Int Urol Nephrol       Date:  2015-06-21       Impact factor: 2.370

Review 10.  Recommendations for the Implementation of Hospital Based HTA in Poland: Lessons Learned From International Experience.

Authors:  Małgorzata Gałązka-Sobotka; Iwona Kowalska-Bobko; Krzysztof Lach; Aneta Mela; Maciej Furman; Iga Lipska
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.